| Date Filed | Type | Description |
| 08/17/2023 |
4
| Klausner Richard (Director) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Sold 58,020 shares
@ $2.28, valued at
$132.3k
|
|
| 08/11/2023 |
4
| Lang Matthew (Chief Business Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 2,250,000 options to buy
@ $2.31, valued at
$5.2M
|
|
| 07/20/2023 |
3
| Lang Matthew (Chief Business Officer) has filed a Form 3 on Lyell Immunopharma, Inc. |
| 02/28/2023 |
4
| Hill Stephen J. (Chief Technical Ops. Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 900,000 options to buy
@ $2.13, valued at
$1.9M
|
|
| 02/28/2023 |
4
| Albertson Tina M. (Chief Medical Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.13, valued at
$1.5M
|
|
| 02/28/2023 |
4
| Lee Gary K. (Chief Scientific Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 600,000 options to buy
@ $2.13, valued at
$1.3M
|
|
| 02/28/2023 |
4
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 245,000 options to buy
@ $2.13, valued at
$521.9k
|
|
| 02/28/2023 |
4
| Newton Charles W. (CFO) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.13, valued at
$1.5M
|
|
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2022 |
4
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 715,000 options to buy
@ $6.91, valued at
$4.9M
|
|
| 10/03/2022 |
3
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 3 on Lyell Immunopharma, Inc. |
| 09/27/2022 |
4
| Klausner Richard (Director) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Sold 11,100 shares
@ $6.4001, valued at
$71k
|
|
| 09/09/2022 |
4
| Bishop Hans Edgar (Director) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Exercised 145,380 options to buy
@ $0.1, valued at
$14.5k
|
|
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| BRAWLEY OTIS W (Director) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 65,000 options to buy
@ $5.31, valued at
$345.2k
|
|
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2022 |
3
| Albertson Tina M. (Chief Medical Officer) has filed a Form 3 on Lyell Immunopharma, Inc. |
| 03/18/2022 |
4
| Turner Heather D (Chief General Counsel) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 300,000 options to buy
@ $5.98, valued at
$1.8M
|
|
| 03/18/2022 |
4
| Newton Charles W. (CFO) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 500,000 options to buy
@ $5.98, valued at
$3M
|
|
| 03/18/2022 |
4
| Homans Elizabeth (CEO) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 1,479,500 options to buy
@ $5.98, valued at
$8.8M
|
|
| 03/18/2022 |
4
| Hill Stephen J. (Chief Technical Ops. Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 700,000 options to buy
@ $5.98, valued at
$4.2M
|
|
| 02/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2022 |
4
| Lee Gary K. (Chief Scientific Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 800,000 options to buy
@ $6.04, valued at
$4.8M
|
|
| 02/04/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/14/2021 |
4
| Homans Elizabeth (CEO) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 1,370,469 options to buy
@ $16.05, valued at
$22M
|
|
| 06/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|